1211443-61-6

Basic information

• Product Name: 7H-Pyrrolo[2,3-d]pyriMidine-6-carboxaMide, 2-chloro-7-cyclopentyl-N,N-diMethyl-
• Synonyms: 7H-Pyrrolo[2,3-d]pyriMidine-6-carboxaMide, 2-chloro-7-cyclopentyl-N,N-diMethyl-;2-chloro-7-cyclopentyl-N,N-diMethyl-7H-pyrrolo[2,3-d]pyriMidine-6-carboxaMide;RIBOCICLIB INT;Ribociclib-1;7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide;2-chloro-7-cyclopentyl-N,N-diMethyl-7H-pyrrolo[2,3-d]pyriMidine-6-arboxaMide;2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;EOS-60967
• CAS NO: 1211443-61-6
• Molecular Formula: C₁₄H₁₇ClN₄O
• Molecular Weight: 292.76398
• EINECS: 1592732-453-0
• Mol File: 1211443-61-6.mol

Chemical Properties

• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Vapor Pressure: 0-0Pa at 20-25℃
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.78±0.30(Predicted)
• CAS DataBase Reference: 7H-Pyrrolo[2,3-d]pyriMidine-6-carboxaMide, 2-chloro-7-cyclopentyl-N,N-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 7H-Pyrrolo[2,3-d]pyriMidine-6-carboxaMide, 2-chloro-7-cyclopentyl-N,N-diMethyl-(1211443-61-6)
• EPA Substance Registry System: 7H-Pyrrolo[2,3-d]pyriMidine-6-carboxaMide, 2-chloro-7-cyclopentyl-N,N-diMethyl-(1211443-61-6)

Safety Data

• Hazardous Substances Data: 1211443-61-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 2-chloro-7-cyclopentyl-N,N-dimethyl, is used as a research compound for exploring its pharmacological properties and potential therapeutic applications. Its unique structure and interactions with biological targets make it a valuable tool for understanding various disease mechanisms and developing novel treatment strategies.
Used in Drug Discovery and Development:
In the drug discovery and development industry, 7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 2-chloro-7-cyclopentyl-N,N-dimethyl, is utilized as a lead compound for the identification and optimization of new drug candidates. Its potential pharmacological activities and interactions with biological targets can guide the design and synthesis of more effective and selective therapeutic agents.
Used in Chemical Synthesis:
7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 2-chloro-7-cyclopentyl-N,N-dimethyl, can also be used as a starting material or intermediate in the synthesis of other related compounds with potential applications in various fields, such as pharmaceuticals, agrochemicals, or materials science.

Upstream product

• 1211443-58-1 2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid 
• 506-59-2 N,N-dimethylammonium chloride 
• 733039-20-8 5-bromo-2-chloro-N-cyclopentylaminopyrimidine-4-amine 
• 2682-34-0 N,N-dimethylpropynamide 
• 1374639-77-6 (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol 
• 124-40-3 dimethyl amine 

Downstream Products

• 1331847-16-5 7-cyclopentyl-2-((diphenylmethylene)amino)-N,N-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine-6-carboxamide 
• 1374639-78-7 N,N‐dimethyl‐7‐cyclopentyl‐2‐{[5‐(4-tert-butoxycarbonylpiperazin‐1‐yl)pyridin‐2‐yl]amino}‐7H‐pyrrolo[2,3‐d]pyrimidine‐6‐carboxamide 
• 1374639-75-4 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate 

Relevant articles and documents

Synthesis method of ribociclib intermediate product and intermediate compound thereof

The invention discloses a synthesis method of a ribociclib intermediate product, which comprises the following steps: by using barbituric acid as a starting material, carrying out chlorination and formylation to obtain a compound 2; and performing condens

POLYMORPHS OF 7-CYCLOPENTYL-N,N-DIMETHYL-2-{[5-(PIPERAZIN-1-YL) PYRIDIN-2-YL]-AMINO}-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to novel crystalline forms of butanedioic acid 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide of formula-1a and process for preparation thereof. The present invention also relates to a process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide. Further, the present application also relates to acid addition salts of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide and process for the preparation thereof.

CDK9 inhibitor, preparation method and application thereof

The invention provides a CDK9 inhibitor, the CDK9 inhibitor is a pyrimidopyrrole kinase inhibitor, and the chemical structural general formula of the CDK9 inhibitor is shown as the formula I in the specification, the CDK9 inhibitor is the pyrimidopyrrole kinase inhibitor, the protein target adapted to the pyrimidopyrrole kinase is serine/threonine kinase CDK9. The CDK9 inhibitor shows relatively high specificity and low cytotoxicity, and the CDK9 inhibitor which is used for preventing or treating tumor growth and metastasis, has selectivity on CDK9, and is small in toxic and side effects and strong in action effect is provided, so that the CDK9 inhibitor is used for regulating and controlling the biological function of CDK9 and inhibiting the growth and proliferation processes of tumors.

Synthesis method of antineoplastic drug ribociclib intermediate

The invention relates to a synthesis method of an antineoplastic drug ribociclib intermediate. The synthesis method includes the following steps that the electrophilic addition reaction is conducted on N,N-dimethylacrylamide and bromine to obtain N,N-dime

Synthesis method of anti-tumor drug ribociclib

The invention relates to a synthesis method of an anti-tumor drug ribociclib. The method mainly comprises the steps of carrying out a reaction between 4-(6-amino-3-pyridyl)-1-piperazinyl tert-butyl formate and 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrol

SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.

AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF

The present invention relates to an improved process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-1a and its novel crystalline for

Key intermediate for synthesis of CDK 4/6 dual inhibitor and preparation method and application of key intermediate

The invention discloses a 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-methanamide intermediate and a preparation method and application thereof. The intermediate is the compoundI, and the preparation method comprises the following st

New intermediate of ribociclib, and synthetic method for preparing ribociclib by using new intermediate

The invention provides a new intermediate compound 6 of ribociclib, and a preparation method thereof, and a synthetic method for preparing ribociclib by using the new intermediate compound 6, whereinthe structure of the compound 6 is defined in the specif

THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS

The invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis. Type 1 or 2 diabetes, obesity, inflammatory disease, o